Allogeneic bone marrow cells that facilitate complete chimerism and eliminate tumor cells express both CD8 and T-cell antigen receptor-αβ

Blood

Volumn 97, Issue 11, 2001, Pages 3458-3465

  Lan, Fengshuo ^a   Zeng, Defu ^a   Huie, Philip ^a   Higgins, John P ^a   Strober, Samuel ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; FAS LIGAND; PERFORIN; T LYMPHOCYTE RECEPTOR ALPHA CHAIN; T LYMPHOCYTE RECEPTOR BETA CHAIN;

ALLOGENIC BONE MARROW TRANSPLANTATION; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; B CELL LYMPHOMA; CHIMERA; GRAFT VERSUS HOST REACTION; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; MONONUCLEAR CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; TOXICITY; WHOLE BODY RADIATION;

EID: 0035383799     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V97.11.3458     Document Type: Article

References (36)

1. Giralt SE, Estey M, Albitar K, et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood. 1997;89:4531-4536.
2. Khouri IF, Keating M, Korbling M, et al. Transplant-lite: induction of graft versus malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol. 1998;16:2817-2824.
3. Slavin S, Nagler A, Naparstek E, et al. Non-myeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood. 1998;91:756-763.
4. McSweeney PA, Storb R. Mixed chimerism: preclinical studies and clinical applications. Biol Blood Marrow Transplant. 1999;5:192-203.
5. Sharabi Y, Sachs DH. Mixed chimerism and permanent specific transplantation tolerance induced by a nonlethal preparative regimen. J Exp Med. 1989;169:493-502.
6. Colson YL, Wren SM, Schuchert MJ, et al. A nonlethal conditioning approach to achieve durable multilineage mixed chimerism and tolerance across major, minor, and hematopoietic histocompatibility barriers. J Immunol. 1995;155:4179-4188.
7. Tomita Y, Khan A, Sykes M. Role of intrathymic clonal deletion and peripheral anergy in transplantation tolerance induced by bone marrow transplantation in mice conditioned with a nonmyeloablative regimen. J Immunol. 1994;153:1087-1098.
8. Sykes M, Szot GL, Swenson K, Pearson DA. Induction of high levels of allogeneic hematopoietic reconstitution and donor-specific tolerance without myelo-suppressive conditioning. Nat Med. 1997;3:783-787.
9. Almaraz R, Ballinger W, Sachs DH, Rosenberg SA. The effect of peripheral lymphoid cells on the incidence of lethal graft versus host disease following allogeneic mouse bone marrow transplantation. J Surg Res. 1983;34:133-144.
10. + T cells reciprocally regulate acute graft versus host disease. J Exp Med. 1999;189:1073-1081.
11. Fauci AS. Human bone marrow lymphocytes, I: distribution of lymphocyte subpopulations in the bone marrow of normal individuals. J Clin Invest. 1975;56:890-110.
12. Gale RP, Opelz G, Kiuchi OM, Golde DW. Thymus-dependent lymphocytes in human bone marrow. J Clin Invest. 1975;56:1491-1498.
13. +Thy-1dim) and lymphoid subsets, and possible predictors of engraftment and graft versus host disease. Blood. 1995;86:2842-2848.
14. Negrin RS, Kusnierz-Glaz CR, Still BJ, et al. Transplantation of enriched and purged peripheral blood progenitor cells from a single apheresis product in patients with non-Hodgkin's lymphoma. Blood. 1995;85:3334-3341.
15. Johnson BD, Truitt RL. Delayed infusion of immunocompetent donor cells after bone marrow transplantation breaks graft-host tolerance and allows for persistent antileukemic reactivity without severe graft-versus-host disease. Blood. 1995;85:3302-3312.
16. Martin P. Donor CD8 cells prevent allogeneic graft rejection in mice: potential implications for marrow transplantation in humans. J Exp Med. 1993;178:703-712.
17. + T cell activity. J Immunol. 1993;150:197-205.
18. + T cells in graft-vs.-leukemia activity and engraftment after allogeneic bone marrow transplantation. Transplantation. 1995;60:355-361.
19. Ito M, Shizuru JA. Graft-vs-lymphoma effect in an allogeneic hematopoietic stem cell transplantation model. Biol Blood Marrow Transplant. 1999;5:357-368.
20. Kaufman, C, Colson Y, Wren S, Watkins S, Simmons R, Ildstad S. Phenotypic characterization of a novel bone marrow-derived cell that facilitates engraftment of allogeneic bone marrow stem cells. Blood. 1994;84:2436-2446.
21. - cells in whole bone marrow facilitate the engraftment of hematopoietic stem cells across allogeneic barriers. Immunity. 1999;11:579-590.
22. Bachar-Lustig E, Rachamim N, Li H-W, Lan F, Reisner Y. Megadose of T-cell-depleted bone marrow overcome MHC barriers in sublethally irradiated mice. Nat Med. 1995;1:1268-1271.
23. 1). Immunol Rev. 1979;48:169-195.
24. Suda T, Nagata S. Purification and characterization of the Fas-ligand that induces apoptosis. J Exp Med. 1994;179:873-879.
25. Kagi D, Vignaux F, Ledermann B, et al. Fas and perforin pathways as major mechanisms of T cell mediated cytotoxicity. Science. 1994;265:528-530.
26. James J, Levy R, Chao NJ. Pathophysiologic mechanisms of acute graft-vs.-host disease. Biol Blood Marrow Transplant. 1999;5:347-356.
27. Mowat A. Antibodies to IFN-gamma prevent immunological mediated intestinal damage in murine graft-versus-host reactions. Immunology. 1989;68:18-23.
28. Ricordi C, Karatzas T, Nerjy J. High-dose donor bone marrow infusions to enhance allograft survival: the effect of timing. Transplantation. 1997;63:7-11.
29. 1 leukemia by allogeneic bone marrow transplantation. J Immunol. 1983;130:2452-2455.
30. Weiss L, Weigensberg M, Morecki S, et al. Characterization of the effector cells of graft vs leukemia following allogeneic bone marrow transplantation in mice inoculated with murine B-cell leukemia. Cancer Immunol Immunother. 1990;31:236-242.
31. 1 tumor and induction of a dormant tumor state in mice chimeric at the major histocompatibility complex. J Immunol. 1886;137:1376-1382.
32. 1 leukemia by allogeneic bone marrow transplantation. J Immunol. 1983;130:2452-2455.
33. Mathew JM, Carreno M, Zucker K. Cellular immune responses of human cadaver donor bone marrow cells and their susceptibility to commonly used immunosuppressive drugs in transplantation. Transplantation. 1998;65:947-955.
34. + bone marrow subpopulation that promotes allogeneic stem cell engraftment. Nature. 2000;8:904-909.
35. Alyea EP, Soiffer RJ, Canning C, et al. Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant. Blood. 1998;91: 3671-3680.
36. Smit WM, Rijnbeek M, van Bergen CA, Fibbe WE, Willemze R, Falkenburg JH. T cells recognizing leukemic CD34(+) progenitor cells mediate the antileukemic effect of donor lymphocyte infusions for relapsed chronic myeloid leukemia after allogeneic stem cell transplantation. Proc Natl Acad Sci U S A. 1998;95:10152-10157.